跳至主要内容
临床试验/NCT01306162
NCT01306162已完成1 期

Relative Bioavailability of a Single Dose of 150 mg Dabigatran Etexilate (Capsule) When Administered Alone or in Combination With a Single Dose of 400 mg Dronedarone Tablet) or in Combination With 400 mg Bid Dronedarone (Tablet) at Steady State in Healthy Male and Female Volunteers (an Open Label, Randomised, Four-sequence, Two Period Cross-over, Phase I Study)

Boehringer Ingelheim1 个研究点 分布在 1 个国家目标入组 36 人开始时间: 2011年2月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
1 期
状态
已完成
入组人数
36
试验地点
1
主要终点
Total Dabigatran: Maximum Measured Concentration (Cmax)

研究概览

简要总结

The objective of the study is to assess the relative bioavailability of a single dose of dabigatran after concomitant multiple oral administration of dronedarone with the aim to investigate whether and to what extent the P-gp inhibitor dronedarone affects pharmacokinetic parameters of dabigatran when administered to healthy subjects

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Crossover
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 50 Years(Adult)
性别
All
接受健康志愿者

入选标准

  • 未提供

排除标准

  • 未提供

研究组 & 干预措施

A: Dabigatran alone (Reference)

Experimental

Capsule, oral administration with 240 mL water

干预措施: Dabigatran etexilate (Drug)

B: Dabigatran plus Dronedarone (Test)

Experimental

Capsule and Tablets, oral administration with 240 mL water

干预措施: Dabigatran etexilate plus dronedarone (Drug)

C: Dabigatran plus Dronedarone (Test)

Experimental

Capsule and Tablets, oral administration with 240 mL water

干预措施: Dabigatran etexilate plus dronedarone (Drug)

D: Dabigatran plus Dronedarone (Test)

Experimental

Capsule and Tablets, oral administration with 240 mL water

干预措施: Dabigatran etexilate plus dronedarone (Drug)

E: Dabigatran plus Dronedarone (Test)

Experimental

Capsule and Tablets, oral administration with 240 mL water

干预措施: Dabigatran etexilate plus dronedarone (Drug)

结局指标

主要结局

Total Dabigatran: Maximum Measured Concentration (Cmax)

时间窗: 1 h before drug administration and 0:30, 1:00, 1:30, 2:00, 3:00, 4:00, 6:00, 8:00, 10:00, 12:00, 24:00, 36:00, 48:00 h after drug administration

Maximum measured concentration of total dabigatran in plasma, per period.

Total Dabigatran: Area Under the Curve 0 to Infinity (AUC0-∞)

时间窗: 1 h before drug administration and 0:30, 1:00, 1:30, 2:00, 3:00, 4:00, 6:00, 8:00, 10:00, 12:00, 24:00, 36:00, 48:00 h after drug administration

Area under the concentration-time curve of total dabigatran in plasma over the time interval from 0 extrapolated to infinity.

次要结局

  • Free Dabigatran: Area Under the Curve 0 to Infinity (AUC0-∞)(1 h before drug administration and 0:30, 1:00, 1:30, 2:00, 3:00, 4:00, 6:00, 8:00, 10:00, 12:00, 24:00, 36:00, 48:00 h after drug administration)
  • Free Dabigatran: Maximum Measured Concentration (Cmax)(1 h before drug administration and 0:30, 1:00, 1:30, 2:00, 3:00, 4:00, 6:00, 8:00, 10:00, 12:00, 24:00, 36:00, 48:00 h after drug administration)

研究者

申办方类型
Industry
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验